# Clinical Trials Data KIT - Document 43

# Utility of Neutrophil Gelatinase-associated Lipocalin (NGAL) in Predicting Renal Impairment, Further Decompensation and Rehospitalization in Acutely Decompensated and Chronic Heart Failure Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT00874289

"eligibilityCriteria": "Inclusion Criteria:\n\n1. Males and Females\n2. Age \\>18years\n3. Confirmed written informed consent\n4. Acute decompensated heart failure cohort defined as:\n\n \* Objective evidence of heart failure (of any cause/etiology) demonstrated by typical symptoms/signs combined with an imaging modality (see appendix for criteria)\n \* Requirement for intravenous diuretic whilst either an inpatient or in an emergency room setting with intravenous diuretics, vasodilators or inotropes\n \* No ejection fraction cut-off will be required, ie both systolic and diastolic heart failure patients can be enrolled\n5. Chronic Heart Failure cohort defined as:\n\n \* Echocardiographic evidence of systolic or diastolic heart failure (see appendix for criteria)\n \* CHF patients in Class III and class IV NYHA symptoms who have had a minimum of one acute decompensated episode in the previous six months\n \* Evidence of impaired renal function (eGFR \\<60 ml/min)\n\nExclusion Criteria:\n\n1. Patients with a history of a psychological illness or condition such as to interfere with the patient's ability to understand the requirements of the study\n2. Not meeting entry criteria for ADAF (as above)\n3. At the discretion of the treating physician",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "Acute and chronic heart failure",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the information provided about the clinical trial's eligibility criteria, the presence of a KIT gene mutation is neither explicitly mentioned as an inclusion nor an exclusion criterion. The criteria focus on factors related to heart failure, such as symptoms, heart ejection fraction, and renal function, rather than specific genetic mutations.  
  
Therefore, a patient with a KIT gene mutation could potentially be eligible for the trial, provided they meet the other specified criteria related to heart failure and do not fall under the exclusion criteria for other reasons. However, it's important for potential participants to discuss their eligibility with the trial coordinators or their healthcare provider for confirmation and to ensure all aspects of their medical history and condition are considered.